Bioequivalence Study is Completed for UBI Pharma’s New Formulation New Drug NDF01, and Will Proceed to NDA Filing Soon 2022 年 11 月 29 日 Read More
UBI Pharma passed the TTQS(Talent Quality-management System) assessment and received the bronze medal 2022 年 11 月 22 日 Read More
The Clinical Study Report of the Phase III Clinical Trial of UBI Pharma’s Recombinant Human Erythropoietin Biosimilar Drug UB-851 Has Been Completed 2022 年 1 月 20 日 Read More
The Production Line of UBI Pharma for Manufacturing Sterile Injectable Drugs Has Been Approved by the U.S. Food and Drug Administration 2019 年 8 月 15 日 Read More
Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption 2019 年 4 月 18 日 Read More
